Annette K Larsen
Overview
Explore the profile of Annette K Larsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
2215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thome M, Borde C, Larsen A, Henriques J, Lenz G, Escargueil A, et al.
Antiviral Res
. 2019 Oct;
172:104615.
PMID: 31580916
Epstein-Barr virus (EBV) is a widely distributed gamma-herpesvirus that has been associated with various cancers mainly from lymphocytic and epithelial origin. Although EBV-mediated oncogenesis has been associated with viral oncogenes...
12.
Delangle R, De Foucher T, Larsen A, Sabbah M, Azais H, Bendifallah S, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31208108
: Endometrial cancer (EC) is the most important gynecological cancer in terms of incidence. microRNAs (miRs), which are post-transcriptional regulators implicated in a variety of cellular functions including carcinogenesis, are...
13.
Bereziat V, Mazurier C, Auclair M, Ferrand N, Jolly S, Marie T, et al.
Cells
. 2019 May;
8(5).
PMID: 31083455
multiple myeloma; bone disease; osteogenesis; adipogenesis; adipose-derived stem cells; bone marrow; senescence; Dickkopf-related protein 1; systemic disease.
14.
Konjevic G, Vuletic A, Mirjacic Martinovic K, Larsen A, Jurisic V
Cytokine
. 2019 Feb;
117:30-40.
PMID: 30784898
Natural killer (NK) cells are innate lymphoid cells that are important effectors in the first line of defense toward transformed cells. This is mediated both by direct cytotoxic mechanisms and...
15.
Chibaudel B, Bachet J, Andre T, Auby D, Desrame J, Deplanque G, et al.
Int J Oncol
. 2019 Feb;
54(4):1433-1445.
PMID: 30720091
Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the effects of aflibercept in...
16.
Francois S, Usunier B, Forgue-Lafitte M, LHomme B, Benderitter M, Douay L, et al.
Stem Cells Transl Med
. 2018 Nov;
8(3):285-300.
PMID: 30451398
We here determine the influence of mesenchymal stem cell (MSC) therapy on the progression of solid tumors. The influence of MSCs was investigated in human colorectal cancer cells as well...
17.
Fotiou D, Sergentanis T, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, et al.
Blood Cancer J
. 2018 Nov;
8(11):102.
PMID: 30405097
Venous thromboembolism (VTE) is a common complication in newly diagnosed symptomatic multiple myeloma (NDMM) patients. We explored cellular and plasma hypercoagulability in NDMM patients to identify relevant biomarkers that can...
18.
Salta S, Papageorgiou L, Larsen A, Van Dreden P, Soulier C, Cokkinos D, et al.
Res Pract Thromb Haemost
. 2018 Oct;
2(4):696-707.
PMID: 30349889
Background: Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Objectives: We investigated the impact of direct and AT-dependent FXa or thrombin inhibitors on thrombus formation. Methods: Whole blood...
19.
Denis J, Mazzola A, Nguyen G, Lacorte J, Brochet C, Larsen A, et al.
Clin Biochem
. 2018 Oct;
64:53-56.
PMID: 30342018
CA 19-9 (carbohydrate antigen 19-9) is a tumor marker widely used for surveillance of patients with pancreatic cancer. However, even high levels of CA 19-9 may not necessarily be cancer-associated...
20.
Carola C, Ghiringhelli F, Kim S, Andre T, Barlet J, Bengrine-Lefevre L, et al.
World J Clin Oncol
. 2018 Sep;
9(5):110-118.
PMID: 30254966
Aim: To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer. Methods: This is a retrospective multicenter cohort, evaluating the efficacy...